43 results
F-3
SCNI
Scinai Immunotherapeutics Ltd
30 Jan 24
Shelf registration (foreign)
4:19pm
profitable and as a result may need to wind up our business and operation;
We will require substantial additional financing to achieve our goals
424B3
SCNI
Scinai Immunotherapeutics Ltd
2 Jan 24
Prospectus supplement
8:24am
profitable and as a result may need to wind up our business and operation;
We will require substantial additional financing to achieve our goals
F-1/A
SCNI
Scinai Immunotherapeutics Ltd
22 Dec 23
Registration statement (foreign) (amended)
9:11am
financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
3 Nov 23
Report of Foreign Private Issuer
8:49am
not only with required resources but also sufficient time to achieve their business goals and, at the same time, the EIB’s impact objectives. The EIB’s
F-1
SCNI
Scinai Immunotherapeutics Ltd
30 Oct 23
Registration statement (foreign)
4:59pm
goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development
424B5
z3v h1jlu
19 Sep 23
Prospectus supplement for primary offering
10:03am
424B2
faowxpr3bennjrd34
28 Aug 23
Prospectus for primary offering
4:01pm
F-3
mklcq pyywe
18 Aug 23
Shelf registration (foreign)
4:16pm
6-K
EX-99.1
ig2m8ab8
12 Jul 23
Report of Foreign Private Issuer
12:00am
10-K
wbv1fhor9bt is87zc
17 Apr 23
Annual report
4:06pm
6-K
EX-99.1
e8de itvrwn
12 Apr 22
Report of Foreign Private Issuer
4:15pm
424B5
mhp0sf1ge y3rl
28 Dec 21
Prospectus supplement for primary offering
5:20pm
424B5
4zcrhvwg470sc23gg1
27 Dec 21
Prospectus supplement for primary offering
6:22am
6-K
EX-99.1
qb3pmv svfen
22 Nov 21
Report of Foreign Private Issuer
6:05am
6-K
EX-99.1
54o8x
23 Mar 21
Current Report
7:54am
424B5
2r40lc
1 Feb 21
Prospectus supplement for primary offering
5:08pm